Peter the Bridge, Saint Petersburg, Russia

News from NEOMED

NEOMED Institute Announces Publication and Clinical Update for NEO6860 an Oral Therapeutic in Development for the Treatment of Chronic Pain

28 March 2017|Announcement| No Comments
- NEO6860 is a promising TRPV1 antagonist designed to avoid on-target side effects - Target engagement and safety profile established in recently published Phase 1 study1 - Promising preliminary results from Phase 2 Study completed in Q1/2017 Montreal, Quebec - March 28

Read complete news

BELLUS Health and NEOMED Institute Announce an Exclusive Worldwide License Agreement for the Development of a Treatment for Chronic Cough

28 February 2017| No Comments
MONTREAL, February 28, 2017 – BELLUS Health (TSX:BLU), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical needs, and NEOMED Institute (NEOMED), a not-for-profit organization bridging the gap between basic research and the commercialization of new drugs, today announced tha

Read complete news

News from NEOMED Institute

15 February 2017| No Comments
NEOMED INSTITUTE ANNOUNCES NEW PRESIDENT & CEO AND CHAIRPERSON OF THE BOARD OF DIRECTORS   Montreal, February 15, 2017 – The NEOMED Institute today announced the appointment of Mr. Donald Olds as President and Chief Executive Officer and the concurrent election of Dr. Laurence Rul

Read complete news

The NEOMED Institute Announces Management Changes

7 December 2016|Announcement| No Comments
Montreal, December 5, 2016 – The NEOMED Institute announced today that Max Fehlmann will be stepping down from his position of CEO of the NEOMED Institute and NEOMED‐LABS at the end of the year. Max, together with Philippe Walker, Chief Scientific Officer of the NEOMED Institute, founded the NEOMED Institute in 2012. Under Max

Read complete news

© 2017 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia